Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 22Glioma 11Neoplasms 6Brain Neoplasms 6Astrocytoma 6Gliosarcoma 5Neuroblastoma 4Sarcoma, Ewing 3Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Wilms Tumor 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Refractory Solid Tumors 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Melanoma 1Lymphoma, Follicular 1Hepatoblastoma 1Ganglioneuroblastoma 1

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1Midazolam 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × Temozolomide × 30 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡